ASH 2024 – Meghan C. Thompson

You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information
Unblock content Accept required service and unblock content


Meghan C. Thompson discusses outcomes in patients with CLL and Richter transformation after discontinuation of non-covalent BTK inhibitors, explores how first-line treatment duration in CLL can be personalized based on MRD kinetics, and highlights the potential of innovative approaches like BTK degraders and bispecific antibodies in relapsed/refractory CLL.

Here is the full ASH 2024 report.